SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Upgraded by Zacks Research

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Several other research firms also recently issued reports on SABS. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Friday, April 10th. Wall Street Zen downgraded SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. HC Wainwright upped their price objective on SAB Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday. Chardan Capital upped their price objective on SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Finally, Rodman & Renshaw reaffirmed a “buy” rating and set a $13.00 price objective on shares of SAB Biotherapeutics in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

SAB Biotherapeutics Price Performance

SABS opened at $3.62 on Monday. The company’s 50 day simple moving average is $3.86 and its 200-day simple moving average is $3.81. SAB Biotherapeutics has a one year low of $1.60 and a one year high of $6.60. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.46 and a quick ratio of 9.46. The stock has a market capitalization of $184.44 million, a P/E ratio of -1.56 and a beta of 0.55.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.15). Sell-side analysts anticipate that SAB Biotherapeutics will post -1.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. bought a new position in SAB Biotherapeutics in the first quarter valued at approximately $29,000. Kestra Advisory Services LLC boosted its stake in SAB Biotherapeutics by 434.6% in the first quarter. Kestra Advisory Services LLC now owns 61,741 shares of the company’s stock valued at $236,000 after acquiring an additional 50,191 shares during the last quarter. Perceptive Advisors LLC bought a new position in SAB Biotherapeutics in the fourth quarter valued at approximately $3,004,000. Millennium Management LLC bought a new position in SAB Biotherapeutics in the fourth quarter valued at approximately $1,212,000. Finally, Balyasny Asset Management L.P. bought a new position in SAB Biotherapeutics in the fourth quarter valued at approximately $1,778,000. 7.82% of the stock is owned by institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.